Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sichuan Yiaso Pharmaceutical Technology
Chengdu, Sichuan, Chinayiaso.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Sichuan Yiaso Pharmaceutical Technology is a China-based biotechnology company focused on the discovery and development of innovative small molecule therapeutics for metabolic diseases and oncology. The company specializes in the development of oral incretin mimetics, including GLP-1, GIP, and glucagon receptor agonists, aimed at treating conditions such as type 2 diabetes and obesity. Yiaso leverages its expertise in medicinal chemistry to create differentiated candidates with improved bioavailability and patient compliance. Its lead programs are currently advancing through early-stage clinical trials in China.
- Therapeutic areas
- EndocrinologyGastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Sichuan Yiaso Pharmaceutical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sichuan Yiaso Pharmaceutical Technology.